162 related articles for article (PubMed ID: 25887663)
41. The tumor microenvironment and its role in promoting tumor growth.
Whiteside TL
Oncogene; 2008 Oct; 27(45):5904-12. PubMed ID: 18836471
[TBL] [Abstract][Full Text] [Related]
42. The immunosuppressive molecule HLA-G and its clinical implications.
González A; Rebmann V; LeMaoult J; Horn PA; Carosella ED; Alegre E
Crit Rev Clin Lab Sci; 2012; 49(3):63-84. PubMed ID: 22537084
[TBL] [Abstract][Full Text] [Related]
43. How tumours escape mass destruction.
Stewart TJ; Abrams SI
Oncogene; 2008 Oct; 27(45):5894-903. PubMed ID: 18836470
[TBL] [Abstract][Full Text] [Related]
44. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
45. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients.
Własiuk P; Tomczak W; Zając M; Dmoszyńska A; Giannopoulos K
Hum Immunol; 2013 Dec; 74(12):1592-7. PubMed ID: 23994589
[TBL] [Abstract][Full Text] [Related]
46. TGF-β induces HLA-G expression through inhibiting miR-152 in gastric cancer cells.
Guan Z; Song B; Liu F; Sun D; Wang K; Qu H
J Biomed Sci; 2015 Dec; 22():107. PubMed ID: 26627200
[TBL] [Abstract][Full Text] [Related]
47. Tumor border sharpness correlates with HLA-G expression in low-grade gliomas.
Wang Y; Fan X; Li H; Lin Z; Bao H; Li S; Wang L; Jiang T; Fan Y; Jiang T
J Neuroimmunol; 2015 May; 282():1-6. PubMed ID: 25903722
[TBL] [Abstract][Full Text] [Related]
48. Lateral organization of the ICAM-1 molecule at the surface of human lymphoblasts: a possible model for its co-distribution with the IL-2 receptor, class I and class II HLA molecules.
Bene L; Balázs M; Matkó J; Möst J; Dierich MP; Szöllösi J; Damjanovich S
Eur J Immunol; 1994 Sep; 24(9):2115-23. PubMed ID: 7916294
[TBL] [Abstract][Full Text] [Related]
49. Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells.
Ke X; Jia L; Wang J; Wang D
Chin Med J (Engl); 2003 Jan; 116(1):78-84. PubMed ID: 12667394
[TBL] [Abstract][Full Text] [Related]
50. The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface.
Tilburgs T; Evans JH; Crespo ÂC; Strominger JL
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13312-7. PubMed ID: 26460007
[TBL] [Abstract][Full Text] [Related]
51. A simple trogocytosis-based method to detect, quantify, characterize and purify antigen-specific live lymphocytes by flow cytometry, via their capture of membrane fragments from antigen-presenting cells.
Daubeuf S; Puaux AL; Joly E; Hudrisier D
Nat Protoc; 2006; 1(6):2536-42. PubMed ID: 17406507
[TBL] [Abstract][Full Text] [Related]
52. HLA-G in testicular germ cell tumors.
Karagöz B; Haholu A; Ozgün A; Bilgi O; Tunçel T; Emirzeoğlu L; Celik S; Demirel D
Oncol Res Treat; 2014; 37(5):245-8. PubMed ID: 24853783
[TBL] [Abstract][Full Text] [Related]
53. Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.
Le Page ME; Goodridge JP; John E; Christiansen FT; Witt CS
J Immunol; 2014 Jan; 192(2):732-40. PubMed ID: 24337374
[TBL] [Abstract][Full Text] [Related]
54. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
Ochs K; Sahm F; Opitz CA; Lanz TV; Oezen I; Couraud PO; von Deimling A; Wick W; Platten M
J Neuroimmunol; 2013 Dec; 265(1-2):106-16. PubMed ID: 24090655
[TBL] [Abstract][Full Text] [Related]
55. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines.
Giacomini P; Giorda E; Fraioli R; Nicotra MR; Vitale N; Setini A; Delfino L; Morabito A; Benevolo M; Venturo I; Mottolese M; Ferrara GB; Natali PG
Cancer Res; 1999 Jun; 59(11):2657-67. PubMed ID: 10363989
[TBL] [Abstract][Full Text] [Related]
56. Intercellular transfer of HLA-G: its potential in cancer immunology.
Lin A; Yan WH
Clin Transl Immunology; 2019; 8(9):e1077. PubMed ID: 31489189
[TBL] [Abstract][Full Text] [Related]
57. Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes.
Mattei F; Andreone S; Spadaro F; Noto F; Tinari A; Falchi M; Piconese S; Afferni C; Schiavoni G
iScience; 2022 Oct; 25(10):105110. PubMed ID: 36185368
[TBL] [Abstract][Full Text] [Related]
58. Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions.
Fiorcari S; Strati P; Dondi E
Front Immunol; 2024; 15():1407981. PubMed ID: 38690284
[No Abstract] [Full Text] [Related]
59. Photo-Driven In Situ Solidification of Whole Cells through Inhibition of Trogocytosis for Immunotherapy.
Liu H; Huang K; Zhang H; Liu X; Jiang H; Wang X
Research (Wash D C); 2024; 7():0318. PubMed ID: 38384327
[TBL] [Abstract][Full Text] [Related]
60. Monitoring Cell Proliferation by Dye Dilution: Considerations for Panel Design.
Tario JD; Soh KT; Wallace PK; Muirhead KA
Methods Mol Biol; 2024; 2779():159-216. PubMed ID: 38526787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
